You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLercanidipine
Accession NumberDB00528  (APRD00193)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionLercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Structure
Thumb
Synonyms
Lercanidipine
Lercanil
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV7XTJ4R0BH
CAS number100427-26-7
WeightAverage: 611.7272
Monoisotopic: 611.299536059
Chemical FormulaC36H41N3O6
InChI KeyInChIKey=ZDXUKAKRHYTAKV-UHFFFAOYSA-N
InChI
InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3
IUPAC Name
3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropylamine
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Aralkylamine
  • Dihydropyridine
  • Hydropyridine
  • Dicarboxylic acid or derivatives
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Organic nitro compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
PharmacodynamicsLercanidipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Lercanidipine is similar to other peripheral vasodilators. Lercanidipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Mechanism of actionBy deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9474
Blood Brain Barrier-0.9611
Caco-2 permeable-0.7039
P-glycoprotein substrateSubstrate0.9085
P-glycoprotein inhibitor IInhibitor0.9132
P-glycoprotein inhibitor IIInhibitor0.8957
Renal organic cation transporterNon-inhibitor0.7439
CYP450 2C9 substrateNon-substrate0.8448
CYP450 2D6 substrateNon-substrate0.8924
CYP450 3A4 substrateSubstrate0.7579
CYP450 1A2 substrateInhibitor0.6321
CYP450 2C9 inhibitorInhibitor0.7247
CYP450 2D6 inhibitorInhibitor0.5933
CYP450 2C19 inhibitorInhibitor0.7625
CYP450 3A4 inhibitorInhibitor0.5715
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7709
Ames testNon AMES toxic0.5517
CarcinogenicityNon-carcinogens0.668
BiodegradationNot ready biodegradable0.9895
Rat acute toxicity2.8614 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5761
hERG inhibition (predictor II)Non-inhibitor0.6908
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP6.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000156 mg/mLALOGPS
logP6.42ALOGPS
logP6.41ChemAxon
logS-6.6ALOGPS
pKa (Strongest Basic)9.36ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area113.69 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity177.85 m3·mol-1ChemAxon
Polarizability65.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Rapolu Raji Reddy, Dasari Muralidhara Reddy, Dandamudi Satish Kumar, " NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE." U.S. Patent US20090227800, issued September 10, 2009.

US20090227800
General References
  1. Lin TH, Voon WC, Yen HW, Huang CH, Su HM, Lai WT, Sheu SH: Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters. Kaohsiung J Med Sci. 2006 Apr;22(4):177-83. [PubMed:16679299 ]
  2. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF, Tanus-Santos JE: Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006 Jan;47(1):117-22. [PubMed:16424795 ]
  3. Agrawal R, Marx A, Haller H: Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens. 2006 Jan;24(1):185-92. [PubMed:16331117 ]
External Links
ATC CodesC09DB08C08CA13C09BB02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Lercanidipine.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Lercanidipine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Lercanidipine.
AcebutololLercanidipine may increase the hypotensive activities of Acebutolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Lercanidipine.
AliskirenLercanidipine may increase the hypotensive activities of Aliskiren.
AlprenololLercanidipine may increase the hypotensive activities of Alprenolol.
AmbrisentanLercanidipine may increase the hypotensive activities of Ambrisentan.
AmifostineLercanidipine may increase the hypotensive activities of Amifostine.
AmiodaroneThe serum concentration of Lercanidipine can be increased when it is combined with Amiodarone.
AmlodipineAmlodipine may increase the hypotensive activities of Lercanidipine.
AmobarbitalThe metabolism of Lercanidipine can be increased when combined with Amobarbital.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Lercanidipine.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lercanidipine.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Lercanidipine.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Lercanidipine.
AprepitantThe serum concentration of Lercanidipine can be increased when it is combined with Aprepitant.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Lercanidipine.
AtazanavirThe serum concentration of Lercanidipine can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Lercanidipine.
AtomoxetineThe metabolism of Lercanidipine can be decreased when combined with Atomoxetine.
AtosibanThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Atosiban.
Atracurium besylateLercanidipine may increase the neuromuscular blocking activities of Atracurium besylate.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Lercanidipine.
BarbitalThe metabolism of Lercanidipine can be increased when combined with Barbital.
BenazeprilLercanidipine may increase the hypotensive activities of Benazepril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Lercanidipine.
BenmoxinBenmoxin may increase the hypotensive activities of Lercanidipine.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Lercanidipine.
BepridilLercanidipine may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Lercanidipine.
BethanidineBethanidine may increase the hypotensive activities of Lercanidipine.
BexaroteneThe serum concentration of Lercanidipine can be decreased when it is combined with Bexarotene.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Lercanidipine.
BimatoprostLercanidipine may increase the hypotensive activities of Bimatoprost.
BisoprololLercanidipine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Lercanidipine can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Lercanidipine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Lercanidipine can be decreased when it is combined with Bosentan.
BosentanLercanidipine may increase the hypotensive activities of Bosentan.
BretyliumLercanidipine may increase the hypotensive activities of Bretylium.
BrimonidineLercanidipine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Lercanidipine.
BupranololLercanidipine may increase the hypotensive activities of Bupranolol.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Lercanidipine.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Lercanidipine.
CandesartanLercanidipine may increase the hypotensive activities of Candesartan.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Lercanidipine.
CandoxatrilLercanidipine may increase the hypotensive activities of Candoxatril.
CaptoprilLercanidipine may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Lercanidipine can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Lercanidipine.
CarteololCarteolol may increase the hypotensive activities of Lercanidipine.
CarvedilolLercanidipine may increase the hypotensive activities of Carvedilol.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Lercanidipine.
CeliprololLercanidipine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Lercanidipine can be increased when it is combined with Ceritinib.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Lercanidipine.
ChlorothiazideLercanidipine may increase the hypotensive activities of Chlorothiazide.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Lercanidipine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Lercanidipine.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Lercanidipine.
CilazaprilLercanidipine may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Lercanidipine can be increased when it is combined with Cimetidine.
ClarithromycinThe serum concentration of Lercanidipine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Lercanidipine can be decreased when combined with Clemastine.
ClonidineLercanidipine may increase the hypotensive activities of Clonidine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lercanidipine.
ClotrimazoleThe metabolism of Lercanidipine can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Lercanidipine can be increased when it is combined with Cobicistat.
ConivaptanThe serum concentration of Lercanidipine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Lercanidipine can be decreased when combined with Crizotinib.
CryptenamineLercanidipine may increase the hypotensive activities of Cryptenamine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Lercanidipine.
CyclosporineThe metabolism of Lercanidipine can be decreased when combined with Cyclosporine.
CyclothiazideLercanidipine may increase the hypotensive activities of Cyclothiazide.
DabrafenibThe serum concentration of Lercanidipine can be decreased when it is combined with Dabrafenib.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Lercanidipine.
DarunavirThe serum concentration of Lercanidipine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Lercanidipine can be increased when it is combined with Dasatinib.
DebrisoquinLercanidipine may increase the hypotensive activities of Debrisoquin.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Lercanidipine.
DeferasiroxThe serum concentration of Lercanidipine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Lercanidipine can be decreased when combined with Delavirdine.
DeserpidineLercanidipine may increase the hypotensive activities of Deserpidine.
DexamethasoneThe serum concentration of Lercanidipine can be decreased when it is combined with Dexamethasone.
DiazoxideDiazoxide may increase the hypotensive activities of Lercanidipine.
DihydroergotamineThe metabolism of Lercanidipine can be decreased when combined with Dihydroergotamine.
DiltiazemDiltiazem may increase the hypotensive activities of Lercanidipine.
DorzolamideLercanidipine may increase the hypotensive activities of Dorzolamide.
DoxazosinLercanidipine may increase the hypotensive activities of Doxazosin.
DoxycyclineThe metabolism of Lercanidipine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Lercanidipine can be decreased when combined with Dronedarone.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Lercanidipine.
EfavirenzThe serum concentration of Lercanidipine can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Lercanidipine.
EfonidipineLercanidipine may increase the hypotensive activities of Efonidipine.
EnalaprilLercanidipine may increase the hypotensive activities of Enalapril.
EnalaprilatLercanidipine may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Lercanidipine can be decreased when it is combined with Enzalutamide.
EpoprostenolLercanidipine may increase the hypotensive activities of Epoprostenol.
EprosartanLercanidipine may increase the hypotensive activities of Eprosartan.
ErythromycinThe metabolism of Lercanidipine can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Lercanidipine can be decreased when it is combined with Eslicarbazepine acetate.
EtravirineThe serum concentration of Lercanidipine can be decreased when it is combined with Etravirine.
FelodipineLercanidipine may increase the hypotensive activities of Felodipine.
FenoldopamLercanidipine may increase the hypotensive activities of Fenoldopam.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lercanidipine.
FluconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Lercanidipine.
FluvoxamineThe metabolism of Lercanidipine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Lercanidipine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Lercanidipine can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Lercanidipine.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Lercanidipine.
FosphenytoinThe metabolism of Lercanidipine can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Lercanidipine.
Fusidic AcidThe serum concentration of Lercanidipine can be increased when it is combined with Fusidic Acid.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Lercanidipine.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Lercanidipine.
GuanabenzLercanidipine may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Lercanidipine.
GuanethidineLercanidipine may increase the hypotensive activities of Guanethidine.
GuanfacineLercanidipine may increase the hypotensive activities of Guanfacine.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Lercanidipine.
HexamethoniumLercanidipine may increase the hypotensive activities of Hexamethonium.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Lercanidipine.
HexobarbitalThe metabolism of Lercanidipine can be increased when combined with Hexobarbital.
HydracarbazineHydracarbazine may increase the hypotensive activities of Lercanidipine.
HydralazineLercanidipine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideLercanidipine may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideLercanidipine may increase the hypotensive activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Lercanidipine can be increased when it is combined with Idelalisib.
IloprostIloprost may increase the hypotensive activities of Lercanidipine.
ImatinibThe metabolism of Lercanidipine can be decreased when combined with Imatinib.
IndapamideLercanidipine may increase the hypotensive activities of Indapamide.
IndenololLercanidipine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Lercanidipine can be increased when it is combined with Indinavir.
IndoraminLercanidipine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Lercanidipine.
IproniazidIproniazid may increase the hypotensive activities of Lercanidipine.
IrbesartanLercanidipine may increase the hypotensive activities of Irbesartan.
IsavuconazoniumThe metabolism of Lercanidipine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Lercanidipine.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Lercanidipine.
IsradipineIsradipine may increase the hypotensive activities of Lercanidipine.
ItraconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Lercanidipine can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Ketoconazole.
LabetalolLercanidipine may increase the hypotensive activities of Labetalol.
LacidipineLercanidipine may increase the hypotensive activities of Lacidipine.
LatanoprostLercanidipine may increase the hypotensive activities of Latanoprost.
LisinoprilLercanidipine may increase the hypotensive activities of Lisinopril.
LofexidineLercanidipine may increase the hypotensive activities of Lofexidine.
LopinavirThe serum concentration of Lercanidipine can be increased when it is combined with Lopinavir.
LosartanLercanidipine may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Lercanidipine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Luliconazole.
MacitentanLercanidipine may increase the hypotensive activities of Macitentan.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium Sulfate.
ManidipineLercanidipine may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Lercanidipine.
MecamylamineLercanidipine may increase the hypotensive activities of Mecamylamine.
MethohexitalThe metabolism of Lercanidipine can be increased when combined with Methohexital.
MethyldopaLercanidipine may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Lercanidipine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Lercanidipine.
MethylphenobarbitalThe metabolism of Lercanidipine can be increased when combined with Methylphenobarbital.
MetipranololLercanidipine may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Lercanidipine.
MetoprololLercanidipine may increase the hypotensive activities of Metoprolol.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Lercanidipine.
MibefradilLercanidipine may increase the hypotensive activities of Mibefradil.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Lercanidipine.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Lercanidipine.
MifepristoneThe metabolism of Lercanidipine can be decreased when combined with Mifepristone.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Lercanidipine.
MinaprineMinaprine may increase the hypotensive activities of Lercanidipine.
MinoxidilMinoxidil may increase the hypotensive activities of Lercanidipine.
MitotaneThe serum concentration of Lercanidipine can be decreased when it is combined with Mitotane.
MivacuriumLercanidipine may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideMoclobemide may increase the hypotensive activities of Lercanidipine.
ModafinilThe serum concentration of Lercanidipine can be decreased when it is combined with Modafinil.
MoexiprilLercanidipine may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Lercanidipine.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Lercanidipine.
MoxonidineLercanidipine may increase the hypotensive activities of Moxonidine.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Lercanidipine.
NadololLercanidipine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Lercanidipine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lercanidipine.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Lercanidipine.
NebivololLercanidipine may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Lercanidipine can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Lercanidipine can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Lercanidipine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Lercanidipine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Lercanidipine.
NicardipineLercanidipine may increase the hypotensive activities of Nicardipine.
NicorandilLercanidipine may increase the hypotensive activities of Nicorandil.
NiguldipineLercanidipine may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Lercanidipine can be decreased when combined with Nilotinib.
NilvadipineLercanidipine may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Lercanidipine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Lercanidipine.
NisoldipineNisoldipine may increase the hypotensive activities of Lercanidipine.
NitrendipineLercanidipine may increase the hypotensive activities of Nitrendipine.
NitroprussideLercanidipine may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Lercanidipine.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Lercanidipine.
ObinutuzumabLercanidipine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Lercanidipine.
OlaparibThe metabolism of Lercanidipine can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Lercanidipine.
OmapatrilatLercanidipine may increase the hypotensive activities of Omapatrilat.
OsimertinibThe serum concentration of Lercanidipine can be increased when it is combined with Osimertinib.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Lercanidipine.
OxprenololLercanidipine may increase the hypotensive activities of Oxprenolol.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Lercanidipine.
PalbociclibThe serum concentration of Lercanidipine can be increased when it is combined with Palbociclib.
PargylineLercanidipine may increase the hypotensive activities of Pargyline.
PenbutololLercanidipine may increase the hypotensive activities of Penbutolol.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Lercanidipine.
PentobarbitalThe metabolism of Lercanidipine can be increased when combined with Pentobarbital.
PentoliniumLercanidipine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Lercanidipine.
PerindoprilLercanidipine may increase the hypotensive activities of Perindopril.
PhenelzinePhenelzine may increase the hypotensive activities of Lercanidipine.
PheniprazinePheniprazine may increase the hypotensive activities of Lercanidipine.
PhenobarbitalThe metabolism of Lercanidipine can be increased when combined with Phenobarbital.
PhenoxybenzamineLercanidipine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Lercanidipine.
PhentolamineLercanidipine may increase the hypotensive activities of Phentolamine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Lercanidipine.
PhenytoinThe metabolism of Lercanidipine can be increased when combined with Phenytoin.
PinacidilLercanidipine may increase the hypotensive activities of Pinacidil.
PindololLercanidipine may increase the hypotensive activities of Pindolol.
PirlindolePirlindole may increase the hypotensive activities of Lercanidipine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Lercanidipine.
PolythiazideLercanidipine may increase the hypotensive activities of Polythiazide.
PosaconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Posaconazole.
PrazosinPrazosin may increase the hypotensive activities of Lercanidipine.
PrimidoneThe metabolism of Lercanidipine can be increased when combined with Primidone.
PropranololLercanidipine may increase the hypotensive activities of Propranolol.
QuinaprilLercanidipine may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Lercanidipine.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Lercanidipine.
RamiprilRamipril may increase the hypotensive activities of Lercanidipine.
RanolazineThe metabolism of Lercanidipine can be decreased when combined with Ranolazine.
RapacuroniumLercanidipine may increase the neuromuscular blocking activities of Rapacuronium.
RasagilineRasagiline may increase the hypotensive activities of Lercanidipine.
RemikirenRemikiren may increase the hypotensive activities of Lercanidipine.
RescinnamineLercanidipine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Lercanidipine.
RifabutinThe metabolism of Lercanidipine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Lercanidipine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Lercanidipine can be increased when combined with Rifapentine.
RiociguatLercanidipine may increase the hypotensive activities of Riociguat.
RitonavirThe serum concentration of Lercanidipine can be increased when it is combined with Ritonavir.
RituximabLercanidipine may increase the hypotensive activities of Rituximab.
SafrazineSafrazine may increase the hypotensive activities of Lercanidipine.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Lercanidipine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lercanidipine.
SaprisartanLercanidipine may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Lercanidipine can be increased when it is combined with Saquinavir.
SecobarbitalThe metabolism of Lercanidipine can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Lercanidipine.
SelexipagLercanidipine may increase the hypotensive activities of Selexipag.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Lercanidipine.
SildenafilSildenafil may increase the antihypertensive activities of Lercanidipine.
SilodosinSilodosin may increase the hypotensive activities of Lercanidipine.
SiltuximabThe serum concentration of Lercanidipine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Lercanidipine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Lercanidipine.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Lercanidipine.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Lercanidipine.
SitaxentanLercanidipine may increase the hypotensive activities of Sitaxentan.
SpiraprilLercanidipine may increase the hypotensive activities of Spirapril.
St. John's WortThe serum concentration of Lercanidipine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Lercanidipine can be increased when it is combined with Stiripentol.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Lercanidipine.
SulfisoxazoleThe metabolism of Lercanidipine can be decreased when combined with Sulfisoxazole.
TadalafilTadalafil may increase the antihypertensive activities of Lercanidipine.
TamsulosinTamsulosin may increase the hypotensive activities of Lercanidipine.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Lercanidipine.
TelaprevirThe serum concentration of Lercanidipine can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Lercanidipine can be increased when it is combined with Telithromycin.
TelmisartanLercanidipine may increase the hypotensive activities of Telmisartan.
TemocaprilLercanidipine may increase the hypotensive activities of Temocapril.
TerazosinTerazosin may increase the hypotensive activities of Lercanidipine.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Lercanidipine.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Lercanidipine.
TerlipressinLercanidipine may increase the hypotensive activities of Terlipressin.
ThiamylalThe metabolism of Lercanidipine can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Lercanidipine can be increased when combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Lercanidipine.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Lercanidipine.
TiboloneLercanidipine may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Lercanidipine can be decreased when combined with Ticlopidine.
TicrynafenLercanidipine may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Lercanidipine.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Lercanidipine.
TocilizumabThe serum concentration of Lercanidipine can be decreased when it is combined with Tocilizumab.
TolazolineLercanidipine may increase the hypotensive activities of Tolazoline.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Lercanidipine.
ToloxatoneToloxatone may increase the hypotensive activities of Lercanidipine.
TorasemideTorasemide may increase the hypotensive activities of Lercanidipine.
TrandolaprilTrandolapril may increase the hypotensive activities of Lercanidipine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lercanidipine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Lercanidipine.
TravoprostTravoprost may increase the hypotensive activities of Lercanidipine.
TreprostinilTreprostinil may increase the hypotensive activities of Lercanidipine.
TrichlormethiazideLercanidipine may increase the hypotensive activities of Trichlormethiazide.
TrimazosinLercanidipine may increase the hypotensive activities of Trimazosin.
TrimethaphanLercanidipine may increase the hypotensive activities of Trimethaphan.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Lercanidipine.
UdenafilUdenafil may increase the antihypertensive activities of Lercanidipine.
UnoprostoneLercanidipine may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Lercanidipine.
VardenafilVardenafil may increase the antihypertensive activities of Lercanidipine.
VenlafaxineThe metabolism of Lercanidipine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Lercanidipine can be decreased when combined with Verapamil.
VoriconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Voriconazole.
XylometazolineLercanidipine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Lercanidipine.
ZiprasidoneThe metabolism of Lercanidipine can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only as a multiple subunit complex.
Gene Name:
CACNG1
Uniprot ID:
Q06432
Molecular Weight:
25028.105 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Burnier M, Pruijm M, Wuerzner G: Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7. doi: 10.1517/17425250903085135. [PubMed:19619074 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23